All pages
Powered by GitBook
1 of 1

Global Expansion Strategy

Apex AI has a three-stage international expansion plan focusing on Korea, the U.S., and Japan, followed by a broader global rollout.

2025–26: Domestic Market Expansion (South Korea)

  • KFDA regulatory approval, and commercialization of AI-powered software for stomach and colorectal cancer diagnostics starting from September 2025.

  • Direct sales targeting major health screening centers and collaborative marketing with the iKooB platform network covering 1,000 hospitals.

  • Collaboration with Next Biomedical and iKooB for AI-driven digestive health solutions, targeting university hospitals and affiliated research hospitals.

2025–26: Entry into the U.S. Market

  • FDA approval application planned for August 2025, with commercialization scheduled for February 2026.

  • Strategic collaborations:

    • Harvard MGH: Onboarding two Harvard-affiliated professors as advisors to facilitate expansion into major U.S. medical institutions.

    • Oracle Healthcare: Establishing strategic partnerships for AI integration.

    • Medtronic: Building collaborative frameworks for medical AI solutions.

  • Leveraging local investment networks to enhance market presence and sustainability.

Japan Expansion

  • Licensing AI technology to leading Japanese endoscopy manufacturers, including Olympus, Pentax, and Fujifilm.

  • Strategic collaboration with CEC, a Fujitsu subsidiary, to commercialize solutions within the Japanese healthcare market, including hospitals and screening centers.

Post-2027: Global Expansion

  • Following successful market establishment in Korea, the U.S., and Japan, Apex AI aims to scale into Europe, China, and other high-demand international markets.

  • Expansion powered by cloud-based AI diagnostic solutions, establishing Apex AI as a global leader in AI-powered gastrointestinal cancer detection.